Literature DB >> 25565435

The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy.

Dewan Md Sakib Hossain1, Priyanka Duttagupta, Marcin Kortylewski.   

Abstract

Entities:  

Keywords:  4-1BB; CTLA-4; STAT3; T cells; aptamers; cancer; immunotherapy; oligonucleotides; siRNA

Mesh：

Substances：

Year:  2015        PMID： 25565435      PMCID： PMC4295639          DOI： 10.4155/tde.14.92

Source DB:  PubMed          Journal:  Ther Deliv        ISSN： 2041-5990


× No keyword cloud information.
  20 in total

1.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

Review 2.  Non-viral vectors for gene-based therapy.

Authors:  Hao Yin; Rosemary L Kanasty; Ahmed A Eltoukhy; Arturo J Vegas; J Robert Dorkin; Daniel G Anderson
Journal:  Nat Rev Genet       Date:  2014-07-15       Impact factor: 53.242

3.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

4.  An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.

Authors:  Charles Preston Neff; Jiehua Zhou; Leila Remling; Jes Kuruvilla; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; John J Rossi; Ramesh Akkina
Journal:  Sci Transl Med       Date:  2011-01-19       Impact factor: 17.956

5.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

Authors:  Marcin Kortylewski; Hong Xin; Maciej Kujawski; Heehyoung Lee; Yong Liu; Timothy Harris; Charles Drake; Drew Pardoll; Hua Yu
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

6.  Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.

Authors:  Alexey Berezhnoy; Iris Castro; Agata Levay; Thomas R Malek; Eli Gilboa
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

7.  T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response.

Authors:  Michail V Sitkovsky
Journal:  Trends Immunol       Date:  2009-02-07       Impact factor: 16.687

8.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

Review 9.  Current progress on aptamer-targeted oligonucleotide therapeutics.

Authors:  Justin P Dassie; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2013-12

10.  Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Mol Ther Nucleic Acids       Date:  2014-06-17       Impact factor: 10.183
View more
  3 in total

1.  Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.

Authors:  Ying Zhang; Xuemei Xie; Pourya Naderi Yeganeh; Dian-Jang Lee; David Valle-Garcia; Karla F Meza-Sosa; Caroline Junqueira; Jiayu Su; Hongbo R Luo; Winston Hide; Judy Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 2.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

3.  GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells.

Authors:  Mobashar Hussain Urf Turabe Fazil; Seow Theng Ong; Madhavi Latha Somaraju Chalasani; Jian Hui Low; Atish Kizhakeyil; Akshay Mamidi; Carey Fang Hui Lim; Graham D Wright; Rajamani Lakshminarayanan; Dermot Kelleher; Navin Kumar Verma
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.